Kuehn Law is investigating Nektar Therapeutics for allegedly misleading shareholders about its REZOLVE-AA clinical trial. The lawsuit claims the company failed to follow trial protocols, overstated the trial's integrity, and made false public statements. This could impact investor trust and the company's stock value. Shareholders who bought stock before February 26, 2025, are encouraged to contact the law firm to protect their rights.
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...
Wellington Management Group LLP has notified that it crossed the 5% voting rights threshold in Admiral Group PLC as of November 6, 2026. The group holds a total of 5.01% voting rights through direct shares and financial instruments. This disclosure i...
